CY1114594T1 - Χρηση της [d-meala]3[etval]4-κυκλοσπορινης για την θεραπεια μολυνσης απο ηπατιτιδα c και φαρμακευτικη συνθεση που περιλαμβανει την εν λογω [d-meala]3[etval]4-κυκλοσπορινη - Google Patents

Χρηση της [d-meala]3[etval]4-κυκλοσπορινης για την θεραπεια μολυνσης απο ηπατιτιδα c και φαρμακευτικη συνθεση που περιλαμβανει την εν λογω [d-meala]3[etval]4-κυκλοσπορινη

Info

Publication number
CY1114594T1
CY1114594T1 CY20111100263T CY111100263T CY1114594T1 CY 1114594 T1 CY1114594 T1 CY 1114594T1 CY 20111100263 T CY20111100263 T CY 20111100263T CY 111100263 T CY111100263 T CY 111100263T CY 1114594 T1 CY1114594 T1 CY 1114594T1
Authority
CY
Cyprus
Prior art keywords
cyclosporin
etval
meala
pharmaceutical composition
composition including
Prior art date
Application number
CY20111100263T
Other languages
English (en)
Inventor
Pietro Scalfaro
Jean-Maurice Dumont
Grégoire Vuagniaux
Rolland-Yves Mauvernay
Original Assignee
Debiopharm S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debiopharm S.A. filed Critical Debiopharm S.A.
Publication of CY1114594T1 publication Critical patent/CY1114594T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Η εφεύρεση αυτή αφορά τη χρήση στη θεραπεία μόλυνσης από HCV, είτε ως μεμονωμένοι δραστικοί παράγοντες ή σε συνδυασμό με έναν άλλο δραστικό παράγοντα, μιας κυκλοσπορίνης που έχει αυξημένη συνδετική δραστικότητα προς κυκλοφιλίνη και ουσιαστικά στερείται ανοσοκατασταλτικής δραστικότητας.
CY20111100263T 2004-10-01 2011-03-08 Χρηση της [d-meala]3[etval]4-κυκλοσπορινης για την θεραπεια μολυνσης απο ηπατιτιδα c και φαρμακευτικη συνθεση που περιλαμβανει την εν λογω [d-meala]3[etval]4-κυκλοσπορινη CY1114594T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2004003205 2004-10-01
EP05791430A EP1793844B1 (en) 2004-10-01 2005-10-03 Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection

Publications (1)

Publication Number Publication Date
CY1114594T1 true CY1114594T1 (el) 2016-10-05

Family

ID=34959441

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100263T CY1114594T1 (el) 2004-10-01 2011-03-08 Χρηση της [d-meala]3[etval]4-κυκλοσπορινης για την θεραπεια μολυνσης απο ηπατιτιδα c και φαρμακευτικη συνθεση που περιλαμβανει την εν λογω [d-meala]3[etval]4-κυκλοσπορινη

Country Status (30)

Country Link
US (3) US7439227B2 (el)
EP (1) EP1793844B1 (el)
JP (1) JP4892486B2 (el)
KR (1) KR101191833B1 (el)
CN (1) CN101056648B (el)
AT (1) ATE490778T1 (el)
AU (1) AU2005290984B2 (el)
BR (1) BRPI0515494A (el)
CA (1) CA2580448C (el)
CY (1) CY1114594T1 (el)
DE (1) DE602005025232D1 (el)
DK (1) DK1793844T3 (el)
EA (1) EA012650B1 (el)
ES (1) ES2357587T3 (el)
GE (1) GEP20104960B (el)
HK (1) HK1104236A1 (el)
HR (1) HRP20110169T1 (el)
IL (1) IL182362A0 (el)
MA (1) MA28950B1 (el)
MX (1) MX2007003387A (el)
NZ (1) NZ554412A (el)
PL (1) PL1793844T3 (el)
PT (1) PT1793844E (el)
RS (1) RS51614B (el)
SG (1) SG139750A1 (el)
SI (1) SI1793844T1 (el)
TN (1) TNSN07084A1 (el)
UA (1) UA88484C2 (el)
WO (1) WO2006038088A1 (el)
ZA (1) ZA200702610B (el)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
AU2005261868B2 (en) 2004-07-14 2009-01-15 Novartis Ag Use of a combination of cyclosporine and pegylated interferon for treating hepatitis C (HCV)
US7196161B2 (en) 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
ES2314731T3 (es) 2004-11-22 2009-03-16 Astellas Pharma Inc. Analogo de ciclosporina.
EP1830871A1 (en) 2004-12-23 2007-09-12 Novartis AG Compositions for hcv treatment
CN101084005A (zh) * 2004-12-23 2007-12-05 诺瓦提斯公司 用于黄病毒科治疗的化合物
AU2006259348B2 (en) * 2005-06-17 2010-07-22 Novartis Ag Use of sanglifehrin in HCV
EP1933859A2 (en) 2005-09-30 2008-06-25 Scynexis, Inc. Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection
WO2007041631A1 (en) 2005-09-30 2007-04-12 Scynexis, Inc. ARYIiALKYL AND HETEROARYLALKYL DERIVATIVES OF CYCLOSPORINE A FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTION
JP5218051B2 (ja) 2005-10-26 2013-06-26 アステラス製薬株式会社 新規環状ペプチド化合物
ES2543840T3 (es) 2006-04-11 2015-08-24 Novartis Ag Inhibidores espirocíclicos del VHC/VIH y sus usos
CN101511357B (zh) 2006-05-19 2011-11-02 西尼克斯公司 环孢菌素类化合物及其组合物在制备治疗和预防眼部疾病的药物中的应用
CN101557819A (zh) * 2006-10-12 2009-10-14 诺瓦提斯公司 修饰的环孢素的用途
WO2008069917A2 (en) 2006-11-20 2008-06-12 Scynexis, Inc. Novel cyclic peptides
WO2008139986A1 (en) 2007-05-02 2008-11-20 Astellas Pharma Inc., New cyclic peptide compounds
US8394763B2 (en) 2007-09-26 2013-03-12 Oregon Health & Science University Cyclic undecapeptides and derivatives as multiple sclerosis therapies
WO2009098533A1 (en) * 2008-02-08 2009-08-13 Debiopharm Sa Non -immunosuppressive cyclosporin for the treatment of muscular dystrophy
WO2010002428A2 (en) 2008-06-06 2010-01-07 Scynexis, Inc. Novel macrocyclic peptides
WO2009148615A1 (en) * 2008-06-06 2009-12-10 Scynexis, Inc. Cyclosporin analogs and their use in the treatment of hcv infections
CA2741829A1 (en) * 2008-11-06 2010-05-14 Debio Recherche Pharmaceutique S.A. Cycloundecadepsipeptide compounds and use of said compounds as a medicament
CN102307892A (zh) 2008-12-31 2012-01-04 西尼克斯公司 环孢菌素a的衍生物
WO2010088573A1 (en) 2009-01-30 2010-08-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis c infection
US8481483B2 (en) 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8367053B2 (en) 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8349312B2 (en) 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
US8685917B2 (en) 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
EP2509615A1 (en) 2009-12-09 2012-10-17 Scynexis, Inc. Novel cyclic peptides
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
WO2011141891A1 (en) 2010-05-12 2011-11-17 Debio Recherche Pharmaceutique S.A. Use of cycloundecadepsipeptide compounds
US9217015B2 (en) 2010-07-16 2015-12-22 S&T Global Inc. Cyclosporin derivatives for the treatment and prevention of a viral infection
CN103153330B (zh) 2010-08-12 2017-08-18 美国科技环球有限公司 新的环孢霉素衍生物在病毒感染的治疗和预防中的应用
AU2011311706B2 (en) * 2010-10-05 2015-11-12 Debiopharm S.A. New treatments of Hepatitis C virus infection
BR112013008510A2 (pt) 2010-10-08 2016-07-05 Novartis Ag vitamina e formulações de inibidores de sulfamida ns3
BR112013013166A2 (pt) * 2010-11-30 2016-09-06 Novartis Ag tratamentos da infecção pelo vírus da hepatite c
US9890198B2 (en) 2010-12-03 2018-02-13 S&T Global Inc. Cyclosporin derivatives and uses thereof
JO3337B1 (ar) * 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
BR112013025021A2 (pt) 2011-03-31 2017-03-01 Novartis Ag alisporivir para tratar infecções por vírus de hepatite c.
JP2014509630A (ja) 2011-04-01 2014-04-21 ノバルティス アーゲー Ｂ型肝炎ウイルス単独の感染症またはデルタ肝炎ウイルスとの複合感染症および付随する肝疾患の治療
MX2013011941A (es) * 2011-04-13 2014-05-28 Debiopharm Int Sa Tratamiento de infeccion por el virus de hepatitis c con alisporivir.
BR112014007247A2 (pt) * 2011-09-27 2017-03-28 Novartis Ag alisporivir para o tratamento de infecção por vírus da hepatite c
GB2515941A (en) 2011-10-21 2015-01-07 Abbvie Inc Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon
EA201490836A1 (ru) 2011-10-21 2014-11-28 Эббви Инк. Комбинационное лечение (например, с abt-072 или abt-333) с помощью daa для применения при лечении hcv
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
JP2015516423A (ja) 2012-05-07 2015-06-11 ノバルティス アーゲー アリスポリビルによる薬物動態の調節
AR090964A1 (es) * 2012-05-09 2014-12-17 Novartis Ag Proceso para la elaboracion de undecapeptidos ciclicos
US8906853B2 (en) 2012-11-28 2014-12-09 Enanta Pharmaceuticals, Inc. [N-Me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis C infection
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
WO2015008223A1 (en) 2013-07-17 2015-01-22 Novartis Ag Treatment of hepatitis c virus infection with alisporivir and ribavirin
KR20160045136A (ko) 2013-08-26 2016-04-26 이난타 파마슈티칼스, 인코포레이티드 C형 간염을 예방 또는 치료하기 위한 사이클로스포린 유사체
WO2015136455A1 (en) 2014-03-13 2015-09-17 Novartis Ag New treatments of hepatitis c virus infection
US9669095B2 (en) 2014-11-03 2017-06-06 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
CN109689063A (zh) 2016-04-28 2019-04-26 埃默里大学 含有炔烃的核苷酸和核苷治疗组合物及其相关用途
US11807664B2 (en) 2017-05-12 2023-11-07 Chugai Seiyaku Kabushiki Kaisha Method for producing cyclic organic compound

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757522B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757520B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
GB9811854D0 (en) * 1998-06-02 1998-07-29 Ciba Geigy Ag Organic compounds
JP4350898B2 (ja) * 1998-07-01 2009-10-21 デビオファーム・ソシエテ・アノニム 活性の特徴が改善された新規のシクロスポリン
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
SG139750A1 (en) 2008-02-29
EA012650B1 (ru) 2009-12-30
WO2006038088A1 (en) 2006-04-13
JP4892486B2 (ja) 2012-03-07
KR101191833B1 (ko) 2012-10-16
TNSN07084A1 (en) 2008-06-02
NZ554412A (en) 2011-01-28
CA2580448C (en) 2012-09-18
SI1793844T1 (sl) 2011-05-31
JP2008514690A (ja) 2008-05-08
AU2005290984A1 (en) 2006-04-13
MX2007003387A (es) 2007-05-23
ATE490778T1 (de) 2010-12-15
UA88484C2 (ru) 2009-10-26
CA2580448A1 (en) 2006-04-13
DK1793844T3 (da) 2011-03-21
USRE43371E1 (en) 2012-05-08
HK1104236A1 (en) 2008-01-11
CN101056648A (zh) 2007-10-17
EP1793844B1 (en) 2010-12-08
MA28950B1 (fr) 2007-10-01
GEP20104960B (en) 2010-04-26
EA200700725A1 (ru) 2007-10-26
PL1793844T3 (pl) 2011-05-31
DE602005025232D1 (de) 2011-01-20
PT1793844E (pt) 2011-03-10
KR20070073761A (ko) 2007-07-10
HRP20110169T1 (hr) 2011-04-30
US7772184B2 (en) 2010-08-10
RS51614B (en) 2011-08-31
ES2357587T3 (es) 2011-04-27
US20060252675A1 (en) 2006-11-09
CN101056648B (zh) 2012-08-15
US7439227B2 (en) 2008-10-21
EP1793844A1 (en) 2007-06-13
AU2005290984B2 (en) 2010-09-09
US20090081164A1 (en) 2009-03-26
ZA200702610B (en) 2008-08-27
IL182362A0 (en) 2007-07-24
BRPI0515494A (pt) 2008-07-29

Similar Documents

Publication Publication Date Title
CY1114594T1 (el) Χρηση της [d-meala]3[etval]4-κυκλοσπορινης για την θεραπεια μολυνσης απο ηπατιτιδα c και φαρμακευτικη συνθεση που περιλαμβανει την εν λογω [d-meala]3[etval]4-κυκλοσπορινη
WO2005102392A3 (en) Combinations for treating hiv infection
BRPI0513370A (pt) uso de uma combinação de ciclosporina e interferonas peguilados para tratamento de hepatite c (hcv)
DE69533551D1 (de) Camptothecin arzneimittelkombinationen mit verringerten nebenwirkungen
BR0210056A (pt) composições e métodos para tratamento de hiperplasia
ATE314092T1 (de) Biologische kleber und verfahren zur topischen verabreichung von wirkstoffen
TNSN07304A1 (en) Combination of xolair with immunosuppressive agent
WO2006034001A3 (en) Methods of treating hiv infection
MA26317A1 (fr) Preparations combinees de derives de 1,1-dioxyde de 1,4-benzothiepine avec d'autres principes actifs et leur utilisation.
HUP0105070A2 (hu) Hepatitis B vírus fertőzések megelőzésére és kezelésére szolgáló készlet
TR200301931T2 (tr) Saç gelişiminde 3 konumundaki siklosporin türevlerinin kullanılması
ATE410154T1 (de) Pharmazeutische zusammensetzung enthaltend 2,4- dichlorbenzylalkohol und amylmetakresol
HK1045456A1 (en) Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection
WO2004033479A3 (en) Retroyclins: antiviral and antimicrobial peptides
SE0000303D0 (sv) Novel compounds
JP2006527741A5 (el)
HRP20020071B1 (en) Pharmaceutical composition and preparation thereof
EP1370697A4 (en) PEROXYREDOXIN-BASED MEDICINAL PRODUCTS FOR THE TREATMENT OF HIV-1 INFECTIONS AND METHODS OF USE
WO2002002087A3 (de) Anthelmintika zur verhinderung von parasitären infektionen bei menschen und tieren ii
RU2001100069A (ru) Антгельминтное средство
HUP0402645A2 (hu) Egy glitazont és egy 4-oxobutánsavat tartalmazó gyógyászati készítmény és ennek alkalmazása cukorbetegség kezelésére
UA93036C2 (ru) Лактамные соединения и применение в качестве фармацевтических препаратов
HUP0300083A2 (hu) Készítmény immunszupresszív szerek alkalmazása által indukált citotoxikus hatások kezelésére és/vagy megelőzésére
CU20070072A7 (es) Uso de [d-meala]3-[etval]4-ciclosporina para el tratamiento de infección por hepatitis c y composición farmacéutica que comprende la [d-meala]3-[etval]4-ciclosporina
WO2005056581A3 (en) Peptide able to specifically bind a chemokine receptor and use thereof